MetLife enters its August 5 earnings report on the back of a remarkable analyst consensus shift — one that has yet to be fully tested by the numbers.
The Street has moved decisively bullish in recent weeks. JP Morgan raised its target from $96 to $106 while maintaining Overweight, and TD Cowen lifted its target a full $18 to $105. Across the broader coverage universe, every recent analyst action has been a target raise, with no downgrades in sight. The consensus mean now stands at $97.75 — essentially in line with the current price of $96.13 — which means the stock has largely closed the gap that once made it look cheap. The forward earnings multiple has expanded roughly 0.9x over the past 30 days, and price-to-book has climbed 0.15x in the same window. The re-rating is real, but it leaves less cushion if the print disappoints.
The bull case rests on MetLife's forward growth profile, which ranks in the 92nd percentile on 12-month EPS momentum. Sales grew 8% over the past year and the company has posted a nearly 30% five-year EBIT CAGR. Bears, however, point to the quality gap: EPS surprise ranks only in the 37th percentile, and free cash flow relative to assets has been in negative territory. The stock has surged 13.6% over the past month and 21.8% year-to-date, a run that raises the bar for what the Q2 print needs to deliver. Peer jumped 10% on the week — suggesting some sector-wide tailwind — while and fell roughly 3% each, a reminder that the group is not moving in lockstep.
Short sellers offer no meaningful counterweight here. Short interest has declined roughly 8% over the past month to just 1.95% of the float, with borrow availability near the maximum of the lending pool and cost to borrow a negligible 0.41%. That rules out any squeeze dynamic. Options positioning adds a mild cautious note — the put/call ratio ticked up to 1.27 on July 31, modestly above its 20-day average of 1.21, though well within a normal range at under one standard deviation above the mean.
The print will test whether MetLife's operating fundamentals — underwriting margins, investment income, and reserve adequacy — can justify a valuation that analysts have already repriced upward ahead of the results.
See the live data behind this article on ORTEX.
Open MET on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
